David J. Earp, J.D., Ph.D., has served as the President & CEO of Circle since October 2013. Previously, David held various roles at Geron Corporation (GERN), including chief patent counsel, chief legal officer and senior vice president of corporate transactions, building a broad IP portfolio and playing an integral role in numerous partnering, licensing and collaboration deals. He led the spin-out of Geron’s nuclear transfer technology into StART Licensing, Inc., and its subsequent acquisition by Viagen Corp. (Austin, Texas). He served on the boards of StART and Viagen, including as executive chairman of Viagen and led the sale of the company to TransOva Genetics (subsequently acquired by Intrexon). David was also a member of the board of directors of TA Therapeutics Ltd. (Hong Kong, PRC). He was previously a partner in the intellectual property law firm of Klarquist Sparkman, LLP (Portland, Oregon). He currently also serves as a board member of Sienna Cancer Diagnostics (Melbourne, Australia).
David received his B.Sc. (with first class honours) in microbiology from the University of Leeds, his Ph.D. in biochemistry and molecular biology from the University of Cambridge, and his J.D. (magna cum laude) from the Northwestern School of Law of Lewis and Clark College. He was a postdoctoral research fellow at the University of California, Berkeley / USDA PGEC.
Rajinder Singh, Ph.D., has served as our Chief Scientific Officer since July 2020. From 2016 to 2020, Dr. Singh held the position of Senior Vice President of Research & Pharmaceutics at ChemoCentryx – where he worked on the complement system (C5aR inhibition with avacopan), diverse chemokine receptors (such as CCR1, CCR2, CCR6, CXCR2, CXCR7) and immune-oncology with small molecules targeting PD-1/PD-L1. From 1998 to 2016, Dr. Singh held various management positions including Vice President, Chemistry at Rigel Pharmaceuticals, Inc., where he oversaw the advancement of numerous drug candidates from discovery to clinical development, which included the filing of numerous Investigational New Drug applications leading to the approval of Tavalisse (fostamatinib) a Syk kinase inhibitor in the areas of immunology and oncology. Prior to joining Rigel, Dr. Singh was a lead chemist at Chiron Corporation from 1994 to 1998. From 1992 to 1994, Dr. Singh was a Postdoctoral Fellow at Eli Lilly & Company. Dr. Singh received his Ph.D. degree in Organic Chemistry from the University of Oxford and B.Sc in Chemistry from University of Cardiff.
Dr. F. Andrew Dorr is a medical oncologist with a long history of successful cancer drug development experience, with leadership roles in the successful development of drugs for prevention and treatment of breast cancer including Taxol® (paclitaxel), Nolvadex® (tamoxifen) and Evista® (raloxifene), and Talzenna® (talazoparib for treatment of germline BRCA-mutation related metastatic breast cancer). He has also played central roles in the development of Eulexin® (flutamide) for prostate cancer, Gemzar® (gemcitabine) in pancreatic and non-small cell lung cancers, Treanda® (bendamustine) in chronic lymphocytic leukemia and non-Hodgkin lymphoma as well as Avastin® (bevacizumab) in glioblastoma.
Dr. Dorr has had a successful consulting business in cancer drug development since 2005. Previously, he served as Chief Operating Officer at Salmedix Inc. from April 2003 until August 2004. From June 1996 to March 2003, he served as Vice President of oncology drug development at Isis (now Ionis) Pharmaceuticals, Inc. and served as its Chief Medical Officer. He also served as Clinical Research Physician and then Medical Advisor at Eli Lilly & Company where he was responsible for the strategy for Lilly’s cancer pipeline from pre-clinical through Phase III development. While at the National Cancer Institute, he was responsible for national clinical trial programs in breast, prostate, kidney, bladder and testicular cancers, as well as melanoma.
Dr. Dorr received his B.S. degree from Davidson College and holds his M.D. from the University of North Carolina at Chapel Hill and has over 60 publications on drug development in books and journals.
Evelyn Wang, Ph.D. joined Circle in July 2021 as our VP of Translational Medicine. Prior to Circle, Dr. Wang led Translational Medicine at Exelixis, Inc. where she built a translational team to handle diverse large data analysis from global clinical programs. She oversaw establishment of pharmacodynamic and biomarker strategies for clinical trials, evaluated and coordinated the correlative research for investigator sponsored studies, and established nonclinical/preclinical studies in support of development strategies and research. Programs included Cabozantinib and immune-oncology combination studies, and other small and large molecule programs. At Biomarin Pharmaceutical Inc., she led translational research for Talazoparib and rare genetic disease programs. Prior to Biomarin, she was at Exelixis where she was the translational medicine lead for several oncology pipeline drugs. Earlier experience includes academic and startup environments. She completed her M.S. and Ph.D. at New York University Medical Center and her postdoctoral training at Harvard Medical School.
Constantine Kreatsoulas, Ph.D. - VP, Research Informatics and Computational Chemistry
Constantine Kreatsoulas, Ph.D., has served as our VP of Research Informatics and Computational Chemistry since February, 2021. Dr. Kreatsoulas joined Circle from GlaxoSmithKline (GSK) where he was the Head of US Molecular Design and Interim Head of Computational Toxicology. His responsibilities at GSK included leading structure-based drug design (SBDD) teams as well as the development of informatics tools for quantitative experimental data analytics and drug hazard identification. Previous to his time at GSK, Dr. Kreatsoulas was a Research Fellow at Merck & Co., Inc., where he focused on SBDD, molecular modeling, machine learning, and small molecule safety assessment. While a Postdoctoral Fellow at Bristol-Meyers Squibb, Dr. Kreatsoulas focused on machine learning in predictive toxicology. Dr. Kreatsoulas was awarded a doctorate in Chemistry from Princeton University, holds a Master’s degree in Regulatory Affairs and Quality Assurance from Temple University, and earned his Bachelor’s degree in Mathematics and Chemistry from New York University.
Dr. Aggen has over 20 years of experience in medicinal chemistry. He most recently served as the Senior Director of Medicinal Chemistry at Revolution Medicines and earlier in his career held various positions at Oligiasis, Achaogen, Chemocentryx, Gilead Sciences and Theravance, as well as Associate Professor of Medicinal and Natural Products Chemistry at Northeastern University. Dr. Aggen has successfully led teams engaged in targeted drug discovery against multiple oncology targets including mTORC1 and KRAS, and has experience in the medicinal chemistry of larger molecules, including as an inventor of the aminoglycoside antibiotic plazomicin, now marketed as Zemdri. He also served in the US Marine Corps Reserves. Dr. Aggen was awarded a doctorate in synthetic organic chemistry from the University of California, Irvine, where he studied under Prof. Richard Chamberlin.
Pablo D. Garcia, Ph.D. - Sr. Director, Biology Research
Pablo D. Garcia, Ph.D., is a cellular and molecular biologist with extensive experience in oncology drug discovery and preclinical development. With over 17 years of experience at Chiron Corporation and the Novartis Institutes for Biomedical Research in Emeryville, he made significant contributions to the areas of target identification and validation, the implementation of diverse discovery platforms and the management of a cancer biology discovery group. Pablo has led several drug discovery projects, including the PIM kinase inhibitor project at Chiron/Novartis. As the project leader, he oversaw all stages of preclinical development, from the initial validation of relevance to human disease to delivery of a drug candidate to clinical development. Pablo has a B.A. in Biology, a Masters in Genetics from Universidad Católica de Valparaíso (Chile) and a Ph.D. in Biochemistry from the University of California, San Francisco (UCSF).
Dr. Ramesh Bambal has over 25 years of global work and leadership experience in the pharmaceutical industry. He joined Circle Pharma in May, 2021 as our Senior Director of DMPK. Before joining Circle, he worked as a consultant for pharmaceutical companies in the U.S. Previously, Dr. Bambal has also served as Associate VP at Sun Pharma Advanced Research Company and Senior Director of DMPK and Analytical Chemistry at Daiichi Sankyo in India. There, his responsibilities included supporting early drug discovery, preclinical, and early phase clinical development for a portfolio of oncology, inflammation, infection and CNS drugs. From 2008 to 2011 Dr. Bambal served as Sr. Director, DMPK at Absorption Systems in Exton, PA. At Absorption Systems he was responsible for building DMPK assay portfolio and supporting pharma and biotech customers in their drug discovery endeavor. Earlier in his career, he worked at SmithKline Beecham and GSK in the DMPK department with increasing responsibilities in managing teams for in-vitro, in vivo ADME, metabolite ID, transporter assays and program management. Dr. Bambal earned his Ph.D. in Organic Chemistry from the National Chemical Laboratory in Pune, India and University of Bombay, India. He completed his post-doctoral research in the Department of Chemistry at the University College London, and Department of Medicinal Chemistry at University of Kansas.
Amy Cowgill - Director, Business Operations and Administration
Amy Cowgill brings a wealth of business and technology leadership experience to Circle, having successfully built solutions and organizational capacity in multiple industries for a range of organizations. Prior to joining Circle, Amy worked at Genentech in leadership roles within the Personalized Healthcare business unit and the Bioinformatics department. Prior to Genentech, Amy spent time at Tech and Financial Services organizations where she led initiatives as well as groups that delivered impactful solutions using both data and technology to enable company objectives. Amy holds a Master’s degree in International Development and a Bachelor’s degree in Mathematics.
Bernard Levin is a pharmacologist and cell biologist with over 15 years of experience in research and drug development. He most recently led pharmacology efforts for multiple CAR-T cell therapy programs targeting both solid tumors and hematological malignancies at Kite Pharma, a Gilead company, in Emeryville, CA. His previous roles have included developing TCR-based cell therapies for HIV treatment while managing the CFAR Humanized Mouse Core at the UCLA AIDS Institute under the mentorship of Prof. Scott Kitchen, and developing Myeloid Progenitor Cell therapies to treat neutropenia at Cellerant Therapeutics in San Carlos, CA. Bernard received his B.S. in Biology from the Massachusetts Institute of Technology (MIT).
Sanjay Srivastava, Ph.D. - Principal Scientist, Computational Chemistry
Dr. Sanjay Srivastava has over 20 years of experience in generating and applying Computational Chemistry and Cheminformatics-led solutions to problems in Drug Discovery. He has led or participated in the introduction of several novel computational paradigms for improving drug design strategies. Prior to joining Circle, he set up and led a new CADD section in a Canadian CRO (Paraza Pharma), where he supported several structurally enabled projects for industry and academic clients. Sanjay has also served as a Computational Chemistry and Cheminformatics consultant to the biotech start-up sector. In previous roles in large pharma, he helped to establish and manage a Cheminformatics platform which impacted multiple Antiviral projects (Boehringer-Ingelheim) and was part of the global team that was successful in implementing, applying, and instilling the culture of utilizing machine learning derived in-silico ADME models to drive preclinical research decisions (AstraZeneca). In addition to Antivirals, Sanjay has also supported multiple therapeutic areas, including several CNS/Pain projects that advanced candidate compounds to the clinical phase. Prior to his industry forays, Sanjay completed postdoctoral fellowships at University of Michigan, Ann Arbor and National Research Council, Montreal (Canada). Dr. Srivastava obtained his Ph.D. in Computational Chemistry from Case Western Reserve University. He also holds a Master’s (Chemistry) from IIT, Kanpur (India) and an undergraduate degree from St. Stephen’s College, Delhi University (India).
Siegfried Leung, Ph.D., specializes in computational drug design and has over a decade of experience in macrocycle design and modeling. He joined Circle after undertaking postdoctoral research in the laboratory of Circle founder Matt Jacobson at UC San Francisco. His work there focused on the development of physics-based predictive models for passive membrane permeability and the application of these methods in designing cell permeable cyclic peptides. He was a key member of the Pfizer / Jacobson laboratory collaboration investigating the engineering of permeability into macrocyclic peptides, developing computational protocols for target-based design of permeable macrocycles. Siegfried received a B.S. (cum laude) from University of San Francisco and his Ph.D. in chemistry from Yale University under the mentorship of Prof. William Jorgensen.
Andrew T. Bockus, Ph.D. - Sr. Scientist, Chemistry
Andrew T. Bockus, Ph.D., leads Circle’s chemistry team. Andrew is a chemist with over a decade of experience in the field of passively-permeable peptidic macrocycles. Prior to joining Circle Pharma, Andrew worked in the lab of Prof. Scott Lokey, a co-founder of Circle, where he synthesized natural product-like cyclic peptides and identified drivers of structure-permeability relationships in diverse peptidic scaffolds. He then developed applications for synthetic receptors and taught undergraduate courses in organic chemistry as a postdoc for Prof. Adam Urbach at Trinity University. Andrew holds a B.A. in Chemistry and Biochemistry from Skidmore College and a Ph.D. in Chemistry from the University of California, Santa Cruz.
Catherine Gleason, Ph.D. - Sr. Scientist, Biology Research
Catherine Gleason, Ph.D., received her B.S. in biochemistry from the University of Washington and earned her Ph.D. from the University of Pennsylvania under the mentorship of Prof. Morris Birnbaum. She trained as a postdoctoral research fellow with Prof. Philip Cohen at the Medical Research Council’s Protein Phosphorylation Unit at the University of Dundee, UK, where she studied the interplay of protein phosphorylation and ubiquitylation in Toll-like receptor signaling and the innate immune response. Before joining Circle Pharma, she was an Adjunct Assistant Professor at the University of California San Francisco, investigating the mTOR signaling pathway in regulation of renal metabolism and ion transport.
Li-Fen received her B.S. in Clinical Nutrition from Chun-Shan Medical School in Taiwan and earned her Ph.D. in Molecular Biology and Human Nutrition from the Ohio State University. As a postdoctoral research fellow at the endocrinology division of the school of medicine at Stanford University, Li-Fen investigated the role of adapt immunity in insulin resistance and inflammation in humans. Li-Fen previously worked as a senior scientific researcher at OBD/Genentech, where she supported biomarker discovery and evaluation for anti-PDL1 programs, focusing on Reverse Translation projects and academic collaborations to further the understanding of resistance mechanisms to anti-PD-L1 in Renal Cell Carcinoma. Prior to joining Circle, Li-Fen held a position as a Senior Data Analytics Manager on the Translational Medicine team supervised by Evelyn Wang at Exelixis. She is incredibly excited to leverage her understanding of tumor metabolism and programming skills to develop potential drug targets that address unmet needs in the oncology space. In her free time, Li-Fen also enjoys hiking, gardening, bird watching, and Zumba dance.
Eran started his career in public accounting with KPMG LLP in New York. During the several years he spent at the Big 4, Eran obtained his Certified Public Accountant (CPA) certification. He then spent over 10 years with a number of private industry and public companies. He recently worked as an Accounting Manager at CytomX Therapeutics. Growing up in Israel, Eran spent three years serving in the Israeli Defense Force (IDF). Achieving the rank of Staff Sergeant, he managed a team of 15 personnel. After his military service, Eran moved to New York and obtained his Bachelor of Science in Accounting and Finance, as well as his MBA from the NYU Stern School of Business.
Luis Hernandez is a member of Circle’s chemistry team. Luis has applied his continuous improvement and management experience from his previous role in a manufacturing facility to streamline macrocycle production and information workflows for Circle. Luis previously held positions at Ingredion, Inc. and Formulation Technology, Inc. He holds a B.S. in Chemical Biology from the University of California, Berkeley.
Breena Walton earned a B.S. in Molecular Synthesis at the University of California, San Diego. After studying total synthesis at the University of Pennsylvania under Prof. Madeleine Joullie and earning an M.S., she went on to work at E.I Dupont de Nemours in the Crop Protection division where she was a co-inventor on several patent applications for bicyclic azoles and helped move a product towards market. She subsequently worked in medicinal chemistry at Theravance Biopharma, and now at Circle Pharma in the chemistry team where her work focuses on advanced chemical synthesis and design.
Meisam Nosrati, Ph.D., is an interdisciplinary scientist with track record accomplishments in the fields of biochemistry, structural biology and organic synthesis. Meisam is passionate about contributing to public health via translational research. His postdoc at Emory University was on bacterial aminoglycoside resistance through ribosome methylation under the supervision of Prof. Graeme L. Conn. His Ph.D work at Michigan State University was focused on protein engineering to make novel proteins and protein probes under the supervision of Prof. James H. Geiger. He holds a B.S. and M.S. from University of Tehran in Chemistry and Organic Chemistry, respectively.
Nathan Dupper, Ph.D., earned his doctorate at UCLA studying Synthetic Organic Chemistry under Professor Ohyun Kwon. After completing his graduate studies, he worked as a postdoc in the laboratory of Professor Charles McKenna at USC. Here, he helped develop antifungal agents targeting the bromodomain containing protein Bdf1. Before joining the Circle Pharma team, he worked as a Synthetic Chemist at AIM Biosciences (WuXi). His work is currently directed toward chemical synthesis and design.
Justin A. Shapiro, Ph.D. - Scientist, Organic Chemistry
Justin A. Shapiro, Ph.D., is an organic chemist at Circle Pharma. Justin began his research career synthesizing cannabinoid derivatives under Prof. Mark L. Trudell, after which he worked under Prof. Loretta Jackson Hayes engineering Protein Kinase C mutants of the fungus Aspergillus nidulans. He went on to study iron acquisition systems of human-pathogenic bacteria using organic and biological chemistry under Prof Timothy A. Wencewicz. Prior to joining Circle, Justin worked on the diverted total synthesis of highly functionalized peptide natural products under Prof. William M. Wuest. Justin graduated with a B.S. in Chemistry from Rhodes College and a Ph.D. in Organic Chemistry from Washington University in St. Louis.
Gabriel is a Scientist with experience in solid-phase synthesis of peptides as well as solution-phase synthesis of small molecules. He received his B.S. in Chemistry from UC Berkeley, and Ph.D in Organic Chemistry under Dr. Lam from UC Davis, where he worked on the combinatorial library syntheses of Actinomycin D analogs bearing triazoles. Prior to graduate school, he lectured sophomore Organic Chemistry at San Francisco State University.
Miguel P. Baldomero - Sr. Research Associate, Chemistry
Miguel Baldomero is a member of Circle’s chemistry team where he focuses on macrocycle synthesis. Miguel previously held positions at CS Bio and Bachem Americas. He holds a B.S. in Chemistry from the University of Wisconsin, Oshkosh.
Bryan Lent works with the chemistry team at Circle Pharma and manages lab operations. Bryan holds a B.S. in Biochemistry from California Polytechnic University, San Luis Obispo and undertook post-graduate studies in Biological Chemistry at Ohio State University with Prof. Jen Ottesen.
Frances Hamkins-Indik - Research Associate, Biology
Frances Hamkins-Indik is a research associate at Circle Pharma working with the Biology and Chemistry teams. Frances previously worked in Prof. Phil Crews’ group at UC Santa Cruz as an undergraduate researcher and received their B.S. in Chemistry from UC Santa Cruz.
Yuliana holds a B.S. in Chemistry from UC Santa Cruz. Before graduating, she interned in the Environmental Fate and Metabolism department at Valent USA, where she determined degradation paths of radio-labeled chemicals. Previous to joining Circle’s chemistry team, she worked at Deibel Laboratories where she looked at sample analysis for pesticide content and also worked on analytical method development projects.
Manesh Chand received his B.S. in Pharmaceutical Chemistry from the University of California, Davis. During his time there, he worked as an undergraduate researcher for the Heffern Lab, analyzing metal-binding peptide hormones. Upon receiving his degree, he began working for Eurofins Test America, where he utilized LC-MS/MS to determine the accurate concentration of perfluoroalkyl substances in various sample matrices.
Daphne He received her B.S. in Biochemistry/Chemistry from UC San Diego. Daphne previously worked at Pfizer in La Jolla during her undergraduate studies, first helping with compound management within Sample Logistics and later running enzyme-based assays and working with LC/MS within Biochemistry and Primary Screening.
Megan DeMart earned her B.S in Chemistry from the University of North Florida where she graduated Cum Laude. Megan previously worked under Dr. Bryan Knuckley at the University of North Florida, synthesizing and characterizing inhibitors for the protein arginine methyltransferase (PRMT) family of proteins. She previously held internship positions during her undergraduate studies at both Bacardi and ADPEN laboratories. Megan also enjoyed teaching students and held positions as a Supplemental Instructor (SI) and a peer chemistry tutor.
Gavin Situ is a Research Associate on Circle Pharma’s Biology team. Previously, Gavin performed work under Dr. David Pearce and Dr. Catherine E. Gleason at the University of California, San Francisco on projects in cellular signaling within the context of renal metabolism and ion homeostasis. Gavin earned his Bachelor’s degree in Biological Sciences from the University of Chicago.
Joshua joins Circle Pharma as a Research Associate II, Chemistry. Joshua earned his B.S. in Bioengineering from Santa Clara University. Having previously worked at CS Bio, Joshua synthesized peptides for the R&D department. Later, he moved on to designing and building peptide synthesizers in the Instrumentation department.
Ranya Odeh received her B.S. in Bioengineering from Stanford. During her studies, Ranya worked as an undergraduate researcher in the Cochran lab, generating decoy receptors that inhibit over-expressed cytokines in lung cancer. Ranya previously interned with the Protein Sciences team at Abbvie.
Casey graduated from the University of Maine with her B.S in Marine Sciences with minors in Pre-Med and Chemistry. After graduating, she worked for 8 months as a Lab Technician at Redwood Toxicology, a drug testing facility. She then started her Ph.D. in Medical and Molecular sciences at James Cook University with her research focusing on discovering and characterizing potential peptide-based drug lead candidates from corals. Casey is currently defending her thesis and will be graduating with her Ph.D. soon.
Nick Vaquera is a Laboratory Technician at Circle Pharma, supporting both the Chemistry and Biology teams. In his previous role, Nick worked at BioElectron, where he was responsible for compound management. Receiving an A.S. in Mathematics and Science from City College of San Francisco, Nick served in the US Navy in support of Operation Enduring Freedom and Operation Iraqi Freedom.
Maria Mendoza joins Circle Pharma as a Lab Technician. With previous experience as a Lab Technician at Merck, Maria brings high attention to detail and multi-tasking skills to our laboratory. Prior to finding her true calling working within the biotech industry, Maria was an Administrative Assistant at a local church. Maria is currently pursuing her BS in Biochemistry through Arizona State University online.
Diana joins Circle Pharma as our Contracts Manager. Diana came to us from BMS/MyoKardia where she worked as a Sr. Contracts Specialist in the Legal department. In addition to writing contracts, Diana has served as administrator of the contracts lifecycle management system. Over last 10 years, Diana has worked in the Biotech /Pharmaceutical industry for companies such as Gilead, Biomarin, Santen and Ekso Bionics and has supported trials in Phases I and III, as well as Grants-based Independent research. Diana also brings Finance experience from previous roles as a Business Analyst, Procurement Specialist, and Buyer.
Eleonor is a seasoned Executive Assistant and Office Manager with over 20 years of experience and a track record of strong performance in fast-paced, high-pressure environments. Having held positions in semiconductor, biotech, and fintech start-ups, Eleonor is able to tailor her approach to meet the needs of any organization. From managing executive calendars and providing general staff support, to handling matters related to HR and facilities, Eleonor handles challenges with ease. Prior to Circle, Eleonor worked as an Executive Business Partner at Credit Karma supporting Tax, Savings, and Product Design executives and directors.
Matt Jacobson, Ph.D., is the Chair of the Department of Pharmaceutical Chemistry at UC San Francisco. He earned his Ph.D. in physical chemistry at MIT, and completed post-doctoral research at Oxford and Columbia. Matt’s research focuses on computational biophysics and computer-aided drug design; he is the author of over 120 publications. Software written by Matt and his collaborators is widely used in the pharmaceutical industry; he serves on the Scientific Advisory Board of Schrödinger, LLC, and is also a co-founder of Global Blood Therapeutics (NASDAQ: GBT), Relay Therapeutics and Cedilla Therapeutics. Matt received the NSF CAREER award, an Alfred P. Sloan Fellowship, and a School of Pharmacy teaching award. He has served on the editorial boards of several journals, including Biochemistry and PLoS Computational Biology.
John Josey, Ph.D., served as the President, Chief Executive Officer, and member of the Board of Directors at Peloton Therapeutics from 2013 until its acquisition by Merck in 2019. From 2011 to 2013, he was President and Chief Scientific Officer at Peloton, and from 1998 to 2011, Vice President of Discovery Chemistry at Array Pharma.
Mr. Evangelista joined The Column Group in 2012 and has almost two decades of venture capital industry experience. Previously, he was with Three Arch Partners, and prior to that, Lightspeed Venture Partners. He began his career working for several large money management firms including Fisher Investments and Barclays Global Investors.
Mr. Evangelista is a Certified Public Accountant (inactive) in the state of California and is a member of the American Institute of CPAs and the California Society of CPAs.
Thilo Schroeder, Ph.D., is a partner at Nextech Invest, a Zurich-based oncology-focused investment firm. He previously served on the board of Peloton Therapeutics (acquired by Merck) and Blueprint Medicines. He is currently a board director at IDEAYA Biosciences, Revolution Medicines, PMV Pharma, Silverback Therapeutics and a board observer at Black Diamond Therapeutics.
Walter H. Moos, Ph.D., is the CEO of ShangPharma Innovation and a managing partner at Pandect Bioventures. He retired as President of SRI Biosciences in early 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). Prior to SRI he served as Chairman and CEO of MitoKor (Migenix), and as a Vice President at Chiron (Novartis) and Warner-Lambert / Parke-Davis (Pfizer). His teams have advanced numerous pharmaceutical products from discovery to commercialization. He has served on about 20 business and scientific boards, including Amunix, Oncologic (Aduro), Onyx (Amgen), Rigel and the Biotechnology Industry Organization (BIO).
Walter holds Ph.D. and A.B. degrees in chemistry from UC Berkeley and Harvard, respectively.
Scott Lokey , Ph.D., has been a faculty member in the department of Chemistry and Biochemistry at the University of California Santa Cruz since 2002. He received his Bachelor’s of Science in Chemistry from Trinity University in San Antonio, Texas in 1989, and a Ph.D. in Chemistry from University of Texas, Austin in 1997 under the mentorship of Dr. Brent Iverson. Dr. Lokey held a NIH postdoctoral fellowship at the Harvard Institute of Chemistry and Cell Biology in Boston, Massachusetts, where he worked with Professors Timothy Mitchison and Marc Kirschner on the identification of cyclic peptide modulators of actin dynamics. His current research interests include the basic science underlying cell permeability of cyclic peptides. He has developed methodologies for synthesizing backbone-modified cyclic peptides. Dr. Lokey and Dr. Jacobson have collaborated on the application of computational approaches for predicting membrane permeability in non-Lipinski Rule-of-5 molecules, with a particular focus on macrocyclic peptides. Dr. Lokey co-founded Circle Pharma with Dr. Jacobson.
William G. Kaelin Jr, M.D. - Chair, Scientific Advisory Board
Dr. Kaelin is a Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Kaelin was awarded the 2019 Nobel Prize for Physiology or Medicine, with co-recipients Sir Peter J Ratcliffe and Dr. Gregg L. Semenza, for discoveries related to the mechanisms by which cell sense and respond to oxygen levels. He is an elected member of the National Academy of Sciences, the National Academy of Medicine and the Association of American Physicians, and has been a Howard Hughes Medical Investigator since 1998. Dr. Kaelin’s research seeks to understand how mutations affecting tumor-suppressor genes cause cancer and to lay the foundation for new anticancer therapies. Dr. Kaelin has received numerous recognitions for his work, including the Albert Lasker Basic Medical Research Award, the Princess Takamatsu Award (AACR), the Science of Oncology Award (ASCO) and the Canada Gairdner International Award. Dr. Kaelin obtained his undergraduate and MD degrees from Duke University and completed his training in internal medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in Medical Oncology at the Dana-Farber Cancer Institute, during which time he was a McDonnell Scholar.
Bruce Stillman, Ph.D., FRS – Scientific Advisory Board member
Dr. Stillman is the President and CEO of Cold Spring Harbor Laboratory (CSHL) in New York and previously served as the Director of the NCI-designated CSHL Cancer Center. He is a biochemist and cancer researcher who has made seminal discoveries related to the eukaryotic DNA replication cycle, including the discovery of the Origin Recognition Complex (ORC), a key protein that initiates the process of making chromosomes competent for duplication. His work has provided insights into the complexity of cell replication and has implications for understanding genomic instability and tumor heterogeneity in cancer. Dr. Stillman is an elected member of the US National Academy of Sciences, the American Academy of Arts and Sciences, the Australian Academy of Science, a Fellow of the American Association for Cancer Research, and a Fellow of the Royal Society. He has received multiple awards including the Alfred P Sloan Prize, General Motors Cancer Research Foundation, the Basic Science Award from the Society of Surgical Oncology, the Herbert Tabor Research Award, the Canada Gairdner International Award, the Heineken Prize for Biochemistry and Biophysics and the Order of Australia. Dr. Stillman received his doctorate from the John Curtin School of Medical Research at the Australian National University.
Alan Ashworth, Ph.D., FRS - Scientific Advisory Board member
Dr. Ashworth is the President of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, a Professor of Medicine in the Division of Hematology / Oncology at UCSF and Sr. Vice President for Cancer Services with USCF Health. He previously served as the Chief Executive of the Institute of Cancer Research in London. Dr. Ashworth is a translational biologist whose research is focused on understanding tumor genetics to develop improvements in the treatment and care of cancer patients. He contributed to the identification of the BRCA2 breast cancer susceptibility gene and the development of PARP inhibitors for cancer treatment. Dr. Ashworth is an elected member of the US National Academy of Sciences and the European Molecular Biology Organization (EMBO) and a Fellow of the Royal Society. His work has been recognized with awards including the European Society of Medical Oncology Lifetime Achievement Award, the Drexel Prize in Cancer Biology, the Basser Global Prize, the Meyenburg Foundation Cancer Research Award, the David T. Workman memorial Award of the Samuel Waxman Cancer Center and the Genetics Society Medal. Dr. Ashworth received his doctorate in biochemistry from University College, London.
Dr. Dineli Wickramasinghe has over 20 years of biotech industry experience. Currently as founding partner at DWSO Biopharma Consulting, she advises venture capital firms, investors, biotech startups, biopharma executive leadership and review boards.
Previously, Dr. Wickramasinghe was Chief Scientific Officer at Affinita Biosciences and site head at Amgen San Francisco. She led Translational and Oncology Research at 23andMe and Amgen San Francisco respectively, developing both protein and small molecule therapeutics. Prior to that, she led oncology teams at Genentech and BASF BioResearch, while also serving as adjunct faculty and post-doc mentor.
Dr. Wickramasinghe has a B.A. from Mount Holyoke College in Massachusetts and a Ph.D. from Tufts University in Boston. She completed her post-doctoral fellowship in molecular genetics at the National Cancer Institute in Maryland. She has authored numerous peer reviewed scientific publications, book reviews and presented at national and international conferences, in addition to being an inventor on multiple patents.
Dr. Olson is the Executive Director of Medicinal Chemistry at the Conrad Prebys Center for Chemical Genomics of the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. He previously served as Adjunct Professor in the Institute for Neurodegenerative Diseases at the University of California, San Francisco, a Principal Scientist at Amgen where he was the chemistry lead for Amgen’s MDM2:p53 project and, earlier in his career, a Research Fellow at Merck. Dr. Olson holds a PhD from Yale University, where he worked in the laboratory of Dr. Samuel Danishefsky, and conducted postdoctoral research at U.C. Berkeley.
Dr. Nikolovska-Coleska is an Associate Professor of Pathology, Director of the Molecular & Cellular Pathology Graduate Program at the University of Michigan and Associate Director of Program in Biomedical Sciences at University of Michigan. Her research group focuses on the discovery, design and development of new molecularly targeted therapies for cancer, particularly targeting protein-protein interactions that are involved in programmed cell death and epigenetic regulation. Dr. Nikolovska-Coleska was the recipient of several awards including, Chemical Structure Association Trust (CSA Trust), New Investigator Award from Leukemia Research Foundation, Innovator Award from Harrington Discovery Institute and AACR-Bayer Innovation and Discovery Award. She is an inventor on more than 13 international and US patents and patent applications, contributing to the discovery and development of Debio 1143 (AT-406), a Smac mimetic targeting inhibitors of apoptosis proteins IAPs, which received FDA breakthrough therapy designation for front-line treatment of head & neck cancer. Currently she serves on the Board of Directors of the International Chemical Biology Society (ICBS) and in 2019 was elected President-Elect. Dr. Nikolovska-Coleska received her PhD in pharmaceutical chemistry at the Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, and was a post-doctoral fellow in drug discovery at the University of Michigan.